Patent · US Active

Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)

US8481033B2 · kind B2 · utility

0Cited by

2References

5Claims

0Family size

Assignee

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR

Inventors

Andreas Bikfalvi · Talence, FR
Alexandre Dubrac · Talence, FR
Eric Lacazette · Toulouse, FR
Herve Prats · Toulouse, FR

Key dates

Filing date	Oct 7, 2009
Grant date	Jul 9, 2013
Priority date	—
Expiry date	Oct 7, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/23
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.